Sydnexis gets EC approval for SYD-101 to treat paediatric myopia
The EC approval follows a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP), based on data from the STAR study, evaluating the drug in children...
Vividion acquires WRN inhibitor to enhance oncology pipeline
Molecular Health, Axxam partner to accelerate drug target discovery
Acerand Therapeutics begins Phase 1 trial of ACE-232 in mCRPC
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma
FDA approves Bayer’s Nubeqa for advanced prostate cancer treatment
Analysis
View More
Risks
View MoreSocietal polarisation and its impact on the pharmaceutical industry
Societal polarisation presents significant challenges for the pharmaceutical industry, affecting regulatory landscapes, public trust, innovation, and market dynamics
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry